Relapsed Acute Myeloid Leukemia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Relapsed Acute Myeloid Leukemia – Pipeline Review, H2 2016’, provides an overview of the Relapsed Acute Myeloid Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Relapsed Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Acute Myeloid Leukemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia

The report reviews pipeline therapeutics for Relapsed Acute Myeloid Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Relapsed Acute Myeloid Leukemia therapeutics and enlists all their major and minor projects

The report assesses Relapsed Acute Myeloid Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Relapsed Acute Myeloid Leukemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Actinium Pharmaceuticals, Inc.

ADC Therapeutics Sarl

Aeglea BioTherapeutics, Inc.

Agios Pharmaceuticals, Inc.

Aileron Therapeutics, Inc.

Amgen Inc.

Arog Pharmaceuticals, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

Bio-Cancer Treatment International Limited

BioLineRx, Ltd.

BioSight Ltd.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Celgene Corporation

Cornerstone Pharmaceuticals, Inc.

CSPC Pharmaceutical Group Limited

CTI BioPharma Corp.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

Eli Lilly and Company

EpiZyme, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

FLX Bio, Inc.

FORMA Therapeutics Inc

Fujifilm Corporation

GlaxoSmithKline Plc

GlycoMimetics, Inc.

Igenica Biotherapeutics, Inc.

Incyte Corporation

JW Pharmaceutical Corporation

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

MacroGenics, Inc.

Merck & Co., Inc.

Millennium Pharmaceuticals Inc

NantKwest, Inc.

Novartis AG

Oxford BioTherapeutics Ltd

Pfizer Inc.

Pharma Mar, S.A.

Polaris Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Sunesis Pharmaceuticals, Inc.

TaiGen Biotechnology Co., Ltd.

Teva Pharmaceutical Industries Ltd.

Tolero Pharmaceuticals, Inc.

VioQuest Pharmaceuticals, Inc.

ZIOPHARM Oncology, Inc.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Relapsed Acute Myeloid Leukemia Overview 6

Therapeutics Development 7

Relapsed Acute Myeloid Leukemia - Therapeutics under Development by Companies 9

Relapsed Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 13

Relapsed Acute Myeloid Leukemia - Pipeline Products Glance 14

Relapsed Acute Myeloid Leukemia - Products under Development by Companies 17

Relapsed Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 22

Relapsed Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 23

Relapsed Acute Myeloid Leukemia - Therapeutics Assessment 80

Drug Profiles 100

Relapsed Acute Myeloid Leukemia - Dormant Projects 414

Relapsed Acute Myeloid Leukemia - Discontinued Products 416

Relapsed Acute Myeloid Leukemia - Product Development Milestones 417

Appendix 430

List of Tables

List of Tables

Number of Products under Development for Relapsed Acute Myeloid Leukemia, H2 2016 18

Number of Products under Development for Relapsed Acute Myeloid Leukemia – Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Development by Companies, H2 2016 (Contd..1) 21

Number of Products under Development by Companies, H2 2016 (Contd..2) 22

Number of Products under Development by Companies, H2 2016 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Late Stage Development, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Development, H2 2016 27

Products under Development by Companies, H2 2016 28

Products under Development by Companies, H2 2016 (Contd..1) 29

Products under Development by Companies, H2 2016 (Contd..2) 30

Products under Development by Companies, H2 2016 (Contd..3) 31

Products under Development by Companies, H2 2016 (Contd..4) 32

Products under Investigation by Universities/Institutes, H2 2016 33

Relapsed Acute Myeloid Leukemia – Pipeline by 4SC AG, H2 2016 34

Relapsed Acute Myeloid Leukemia – Pipeline by AbbVie Inc, H2 2016 35

Relapsed Acute Myeloid Leukemia – Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 36

Relapsed Acute Myeloid Leukemia – Pipeline by ADC Therapeutics Sarl, H2 2016 37

Relapsed Acute Myeloid Leukemia – Pipeline by Aeglea BioTherapeutics, Inc., H2 2016 38

Relapsed Acute Myeloid Leukemia – Pipeline by Agios Pharmaceuticals, Inc., H2 2016 39

Relapsed Acute Myeloid Leukemia – Pipeline by Aileron Therapeutics, Inc., H2 2016 40

Relapsed Acute Myeloid Leukemia – Pipeline by Amgen Inc., H2 2016 41

Relapsed Acute Myeloid Leukemia – Pipeline by Arog Pharmaceuticals, Inc., H2 2016 42

Relapsed Acute Myeloid Leukemia – Pipeline by Array BioPharma Inc., H2 2016 43

Relapsed Acute Myeloid Leukemia – Pipeline by Astellas Pharma Inc., H2 2016 44

Relapsed Acute Myeloid Leukemia – Pipeline by AstraZeneca Plc, H2 2016 45

Relapsed Acute Myeloid Leukemia – Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 46

Relapsed Acute Myeloid Leukemia – Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 47

Relapsed Acute Myeloid Leukemia – Pipeline by Bio-Cancer Treatment International Limited, H2 2016 48

Relapsed Acute Myeloid Leukemia – Pipeline by BioLineRx, Ltd., H2 2016 49

Relapsed Acute Myeloid Leukemia – Pipeline by BioSight Ltd., H2 2016 50

Relapsed Acute Myeloid Leukemia – Pipeline by Boehringer Ingelheim GmbH, H2 2016 51

Relapsed Acute Myeloid Leukemia – Pipeline by Boston Biomedical, Inc., H2 2016 52

Relapsed Acute Myeloid Leukemia – Pipeline by Bristol-Myers Squibb Company, H2 2016 53

Relapsed Acute Myeloid Leukemia – Pipeline by Calithera Biosciences, Inc., H2 2016 54

Relapsed Acute Myeloid Leukemia – Pipeline by Celgene Corporation, H2 2016 55

Relapsed Acute Myeloid Leukemia – Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016 56

Relapsed Acute Myeloid Leukemia – Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 57

Relapsed Acute Myeloid Leukemia – Pipeline by CTI BioPharma Corp., H2 2016 58

Relapsed Acute Myeloid Leukemia – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 59

Relapsed Acute Myeloid Leukemia – Pipeline by Eisai Co., Ltd., H2 2016 60

Relapsed Acute Myeloid Leukemia – Pipeline by Eli Lilly and Company, H2 2016 61

Relapsed Acute Myeloid Leukemia – Pipeline by EpiZyme, Inc., H2 2016 62

Relapsed Acute Myeloid Leukemia – Pipeline by Exelixis, Inc., H2 2016 63

Relapsed Acute Myeloid Leukemia – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 64

Relapsed Acute Myeloid Leukemia – Pipeline by FLX Bio, Inc., H2 2016 65

Relapsed Acute Myeloid Leukemia – Pipeline by FORMA Therapeutics Inc, H2 2016 66

Relapsed Acute Myeloid Leukemia – Pipeline by Fujifilm Corporation, H2 2016 67

Relapsed Acute Myeloid Leukemia – Pipeline by GlaxoSmithKline Plc, H2 2016 68

Relapsed Acute Myeloid Leukemia – Pipeline by GlycoMimetics, Inc., H2 2016 69

Relapsed Acute Myeloid Leukemia – Pipeline by Igenica Biotherapeutics, Inc., H2 2016 70

Relapsed Acute Myeloid Leukemia – Pipeline by Incyte Corporation, H2 2016 71

Relapsed Acute Myeloid Leukemia – Pipeline by JW Pharmaceutical Corporation, H2 2016 72

Relapsed Acute Myeloid Leukemia – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 73

Relapsed Acute Myeloid Leukemia – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 74

Relapsed Acute Myeloid Leukemia – Pipeline by MacroGenics, Inc., H2 2016 75

Relapsed Acute Myeloid Leukemia – Pipeline by Merck & Co., Inc., H2 2016 76

Relapsed Acute Myeloid Leukemia – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 77

Relapsed Acute Myeloid Leukemia – Pipeline by NantKwest, Inc., H2 2016 78

Relapsed Acute Myeloid Leukemia – Pipeline by Novartis AG, H2 2016 79

Relapsed Acute Myeloid Leukemia – Pipeline by Oxford BioTherapeutics Ltd, H2 2016 80

Relapsed Acute Myeloid Leukemia – Pipeline by Pfizer Inc., H2 2016 81

Relapsed Acute Myeloid Leukemia – Pipeline by Pharma Mar, S.A., H2 2016 82

Relapsed Acute Myeloid Leukemia – Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 83

Relapsed Acute Myeloid Leukemia – Pipeline by Seattle Genetics, Inc., H2 2016 84

Relapsed Acute Myeloid Leukemia – Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016 85

Relapsed Acute Myeloid Leukemia – Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 86

Relapsed Acute Myeloid Leukemia – Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 87

Relapsed Acute Myeloid Leukemia – Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 88

Relapsed Acute Myeloid Leukemia – Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016 89

Relapsed Acute Myeloid Leukemia – Pipeline by ZIOPHARM Oncology, Inc., H2 2016 90

Assessment by Monotherapy Products, H2 2016 91

Assessment by Combination Products, H2 2016 92

Number of Products by Stage and Target, H2 2016 94

Number of Products by Stage and Mechanism of Action, H2 2016 101

Number of Products by Stage and Route of Administration, H2 2016 108

Number of Products by Stage and Molecule Type, H2 2016 110

Relapsed Acute Myeloid Leukemia – Dormant Projects, H2 2016 425

Relapsed Acute Myeloid Leukemia – Dormant Projects (Contd..1), H2 2016 426

Relapsed Acute Myeloid Leukemia – Discontinued Products, H2 2016 427

List of Figures

List of Figures

Number of Products under Development for Relapsed Acute Myeloid Leukemia, H2 2016 18

Number of Products under Development for Relapsed Acute Myeloid Leukemia – Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Late Stage Development, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Products, H2 2016 27

Assessment by Monotherapy Products, H2 2016 91

Number of Products by Top 10 Targets, H2 2016 93

Number of Products by Stage and Top 10 Targets, H2 2016 93

Number of Products by Top 10 Mechanism of Actions, H2 2016 100

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 100

Number of Products by Routes of Administration, H2 2016 107

Number of Products by Stage and Routes of Administration, H2 2016 107

Number of Products by Molecule Types, H2 2016 109

Number of Products by Stage and Molecule Types, H2 2016 109

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports